Pending FDA Approval for Chronic Weight Management: As of 2023, Eli Lilly and Company, the manufacturer of Mounjaro, has submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval for Mounjaro as a treatment for chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition [4]
This becomes especially important for active women who are strength training, hiking, running, golfing, recovering from injuries, or participating in physical therapy because the body still has physical demands placed on it regardless of appetite levels
If you want a clearer idea of how Botox works, take a look at our treatment page Botox London
From 7 injections/week 1 injection/week Same glycaemic control (HbA1c reduction) Comparable safety to daily basal insulin Backed by the ONWARDS Phase 3 program (~2,600+ patients), Awiqli demonstrated: Strong efficacy Consistent safety profile Flexibility with oral agents & GLP-1 therapies Strategic Takeaways (CI Lens): Convenience = Competitive Edge Improved adherence could translate into better real-world outcomes and stronger payer positioning
&srotate=0)
